Fed. Circ. Revives Jublia IP Over 'Unreasonable' Construction
The Federal Circuit on Friday gave Kaken Pharmaceutical and Bausch Health another chance to prove that a patent covering the antifungal medication Jublia is valid, saying the Patent Trial and Appeal...To view the full article, register now.
Already a subscriber? Click here to view full article